Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517420 | PMC |
| http://dx.doi.org/10.2147/DDDT.S341223 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lomitapide: navigating cardiovascular challenges with innovative therapies.
Mol Biol Rep
October 2024
College of Dental Medicine, Lincoln Memorial University, LMU tower, 1705 St. Mary Street, Knoxville, TN, 37917, USA.
Article Synopsis
- Dyslipidemia is a key risk factor for cardiovascular diseases, and current treatments primarily aim to lower LDL cholesterol levels to prevent conditions like atherosclerosis and myocardial infarction.
- Homozygous Familial Hypercholesterolemia (HoFH) results from mutations in the LDL receptor, leading to very high LDL cholesterol levels, which often do not respond well to standard statin therapy.
- Lomitapide, a microsomal triglyceride transfer protein inhibitor, has been approved for HoFH treatment; it effectively lowers LDL-C levels without affecting the LDL receptor and has been shown to reduce LDL-C by more than 50% in resistant cases.
Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Iran J Basic Med Sci
January 2024
Department of Pharmacology, School of Pharmaceutical Education & Research (SPER), Jamia Hamdard, New Delhi-110062, India.
Objectives: Nephropathy is the most common comorbidity linked to T2D. The present study aimed to examine the potential of saroglitazar in the context of a high-fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Materials And Methods: Molecular docking simulation investigations were conducted on the ligand-binding region of type IV collagen and Kidney injury molecule-1 (KIM-1), using saroglitazar and fenofibrate as the subjects.
Saroglitazar, a PPAR α/γ agonist alleviates 3-Nitropropionic acid induced neurotoxicity in rats: Unveiling the underlying mechanisms.
Neurotoxicology
December 2024
Department of Pharmacology, Shri Vishnu College of Pharmacy (SVCP), Vishnupur, Bhimavaram, West Godavari, Andhra Pradesh 534202, India. Electronic address:
Saroglitazar (SGZ), a peroxisomal proliferated activated receptor α/γ agonist showed neuroprotective effects in various neurodegenerative disorders like Alzheimer's and Parkinson's. However, no studies were performed on Huntington's, so the goal of the current study is to examine the effect of SGZ on Huntington's disease like symptoms induced by 3-Nitropropionic acid. In this protocol, twenty-four rats were divided into four groups, each group consisting of 6 animals.
View Article and Find Full Text PDFPipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
J Clin Transl Hepatol
September 2024
Department of Gastroenterology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- There is a growing global concern over metabolic dysfunction-associated steatotic liver disease (MASLD), yet no licensed medications exist for its treatment.
- Recent research has illuminated the complex nature of MASLD, paving the way for the development of new drugs and repurposing existing ones.
- Treatment strategies focus on four key pathways: antidiabetic medications, managing hepatic lipid accumulation, addressing oxidative stress/inflammation, and targeting gut health, with combination therapies seen as a promising approach for improved effectiveness and reduced side effects.
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.
World J Methodol
June 2024
Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar 751019, Odisha, India.
Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, affecting more than half of the people living with type 2 diabetes (T2D). The relationship between NAFLD and T2D is bidirectional and the presence of one perpetuates the other, which significantly increases the hepatic as well as extrahepatic complications. Until recently, there was no approved pharmacological treatment for NAFLD/ nonalcoholic steatohepatitits (NASH).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!